Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen YHLO Biotech CoSHSE:688575 -1.72%69 EV-to-FCF is 57.97 as of Jul. 21, 2026, which is 462% above its 10-year median of 10.32. GuruFocus rates SHSE:688575 with a GF Score™ of 69/100 and a GF Value™ of ¥14.62 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Shenzhen YHLO Biotech Co ranks worse than 81.4% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shenzhen YHLO Biotech Co's Enterprise Value is ¥5,484 Mil.
Shenzhen YHLO Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥95 Mil. Therefore, Shenzhen YHLO Biotech Co's EV-to-FCF for today is 57.97.
The historical rank and industry rank for Shenzhen YHLO Biotech Co's EV-to-FCF or its related term are showing as below:
SHSE:688575'
s EV-to-FCF Range Over the Past 10 Years
Min: -429.23 Med: 10.32 Max: 1536.07
Current: 57.97
During the past 9 years, the highest EV-to-FCF of Shenzhen YHLO Biotech Co was 1536.07. The lowest was -429.23. And the median was 10.32.
SHSE:688575's EV-to-FCF is ranked worse than 81.4% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.2
vs SHSE:688575: 57.97
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shenzhen YHLO Biotech Co (SHSE:688575) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shenzhen YHLO Biotech Co's PE Ratio (TTM) for today is calculated as:
Shenzhen YHLO Biotech Co's share price for today is ¥9.13.
Shenzhen YHLO Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shenzhen YHLO Biotech Co EV-to-FCF Related Terms
Shenzhen YHLO Biotech Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688575 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen YHLO Biotech Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shenzhen YHLO Biotech Co's EV-to-FCF falls into.
Shenzhen YHLO Biotech Co's current Enterprise Value is ¥5,484 Mil.
Shenzhen YHLO Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen YHLO Biotech Co (SHSE:688575) has a EV-to-FCF of 57.97 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shenzhen YHLO Biotech Co and its competitors. This is 462% above median its historical median of 10.32. According to the industry distribution chart, Shenzhen YHLO Biotech Co ranks #337 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 81.4%.
Is Shenzhen YHLO Biotech Co's EV-to-FCF too high?
Shenzhen YHLO Biotech Co's current EV-to-FCF of 57.97 is 462% above median its 10-year median of 10.32. The Medical Devices & Instruments industry median EV-to-FCF is 23.20. Shenzhen YHLO Biotech Co's value of 57.97 is 149.9% above this industry median. Based on the distribution chart, Shenzhen YHLO Biotech Co ranks #337 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen YHLO Biotech Co ranks #337 out of 414 companies for EV-to-FCF. This places Shenzhen YHLO Biotech Co in the lower half of its industry. The industry median EV-to-FCF is 23.20. Shenzhen YHLO Biotech Co's value of 57.97 is 149.9% above this benchmark. While the company's 10-year median is 10.32 vs. the industry median of 23.20, Shenzhen YHLO Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.20, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen YHLO Biotech Co's current EV-to-FCF of 57.97 is 149.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shenzhen YHLO Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen YHLO Biotech Co's current EV-to-FCF is 57.97, which is 462% above median its own 10-year median of 10.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.62, compared to a current price of ¥9.13 — trading 37.6% below its estimated fair value. The current EV-to-FCF is 57.97, which is 462% above median its 10-year median of 10.32 and 149.9% above the Medical Devices & Instruments industry median of 23.20. Shenzhen YHLO Biotech Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current EV-to-FCF is 57.97 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥9.13 is trading 37.6% below its estimated GF Value™ of ¥14.62.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
EV-to-FCF: 57.97 (462% above median its 10-year median of 10.32)
GF Value™: ¥14.62 vs. price of ¥9.13 (37.6% below fair value)
Industry Position: 149.9% above the Medical Devices & Instruments median (#337 of 414)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
69GF Score
Get the complete analysis for SHSE:688575
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
